Literature DB >> 18269360

Intranasal naloxone for the treatment of suspected heroin overdose.

Debra Kerr1, Paul Dietze, Anne-Maree Kelly.   

Abstract

AIMS: This paper reviews available literature regarding the effectiveness, safety and utility of intranasal (i.n.) naloxone for the treatment of heroin overdose.
METHODS: Scientific literature in the form of published articles during the period January 1984 to August 2007 were identified by searching several databases including Medline, Cinahl and Embase for the following terms: naloxone, narcan, intranasal, nose. The data extracted included study design, patient selection, numbers, outcomes and adverse events.
RESULTS: Reports of the pharmacological investigation and administration of i.n. naloxone for heroin overdose are included in this review. Treatment of heroin overdose by administration of i.n. naloxone has been introduced as first-line treatment in some jurisdictions in North America, and is currently under investigation in Australia.
CONCLUSION: Currently there is not enough evidence to support i.n. naloxone as first-line intervention by paramedics for treatment of heroin overdose in the pre-hospital setting. Further research is required to confirm its clinical effectiveness, safety and utility. If proved effective, the i.n. route may be useful for drug administration in community settings (including peer-based administration), as it reduces risk of needlestick injury in a population at higher risk of blood-borne viruses. Problematically, naloxone is not manufactured currently in an ideal form for i.n. administration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18269360     DOI: 10.1111/j.1360-0443.2007.02097.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  19 in total

1.  A response to the opioid overdose epidemic: naloxone nasal spray.

Authors:  Daniel P Wermeling
Journal:  Drug Deliv Transl Res       Date:  2013-02-01       Impact factor: 4.617

Review 2.  Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access.

Authors:  Daniel P Wermeling
Journal:  Ther Adv Drug Saf       Date:  2015-02

3.  Pharmacokinetics of a new, nasal formulation of naloxone.

Authors:  Ida Tylleskar; Arne Kristian Skulberg; Turid Nilsen; Sissel Skarra; Phatsawee Jansook; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2017-01-31       Impact factor: 2.953

4.  Imaging Sex Differences in Regional Brain Metabolism during Acute Opioid Withdrawal.

Authors:  Giovanni C Santoro; Joseph Carrion; Stephen L Dewey
Journal:  J Alcohol Drug Depend       Date:  2017-04-06

5.  Oxytocin under opioid antagonism leads to supralinear enhancement of social attention.

Authors:  Olga Dal Monte; Matthew Piva; Kevin M Anderson; Marios Tringides; Avram J Holmes; Steve W C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-01       Impact factor: 11.205

Review 6.  A Review of Opioid Overdose Prevention and Naloxone Prescribing: Implications for Translating Community Programming Into Clinical Practice.

Authors:  Shane R Mueller; Alexander Y Walley; Susan L Calcaterra; Jason M Glanz; Ingrid A Binswanger
Journal:  Subst Abus       Date:  2015-03-16       Impact factor: 3.716

7.  Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.

Authors:  Abby M Bailey; Daniel P Wermeling
Journal:  Ann Pharmacother       Date:  2014-02-12       Impact factor: 3.154

Review 8.  Prescription Opioid Misuse, Abuse, and Treatment in the United States: An Update.

Authors:  Kathleen T Brady; Jenna L McCauley; Sudie E Back
Journal:  Am J Psychiatry       Date:  2015-09-04       Impact factor: 18.112

9.  Pitfalls of intranasal naloxone.

Authors:  Matthew Zuckerman; Stacy N Weisberg; Edward W Boyer
Journal:  Prehosp Emerg Care       Date:  2014-05-15       Impact factor: 3.077

10.  Can we prevent drug related deaths by training opioid users to recognise and manage overdoses?

Authors:  Romina Lopez Gaston; David Best; Victoria Manning; Ed Day
Journal:  Harm Reduct J       Date:  2009-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.